Patent ID: 9000021
Filing Date: 2015-04-07
Classification: A61K,A61P

Abstract:
1. A method of treating a bendamustine-responsive condition in a subject requiring restricted fluid and/or sodium intake, comprising a) identifying a subject in need of bendamustine therapy and having a physiological condition requiring restricted fluid and/or sodium intake; b) parenterally administering to said subject a volume of about 100 ml or less of a liquid composition containing: i) from about 0.05 to about 12.5 mg/ml of bendamustine or a pharmaceutically acceptable salt thereof; ii) a solubilizer comprising polyethylene glycol and propylene glycol, the polyethylene glycol being present in an amount of from about 0.3 to about to 45% volume and the propylene glycol being present in an amount of from about 0.03 to about 5% volume; and, optionally iii) a parenterally acceptable diluent over a substantially continuous period of less than or equal to about 30 minutes.